Archer Pharmaceuticals is a leading pharmaceutical company specializing in drug discovery for Alzheimer's disease and other dementias. Founded in 2008, Archer is dedicated to developing convenient and safe medications to slow or prevent the progression of this debilitating condition. Headed by CEO and Chief Scientific Officer Michael Mullan, M.

B. B. S., Ph.

D., and COO and Associate Chief Scientific Officer Fiona Crawford, Ph. D., Archer was established to advance research conducted at the renowned Roskamp Institute in Florida. One of Archer's notable achievements is the clinical development of Nilvadipine, a potential therapy for Alzheimer's disease.

The Phase I/IIA human clinical trial conducted in partnership with Trinity College Dublin demonstrated Nilvadipine's tolerability among Alzheimer's patients. This success paved the way for the Phase III double-blind, placebo-controlled NILVAD study, which concluded in 2017. Ongoing analyses of the trial results are expected to be made public in Q1 2018.

With a mission to combat the increasing prevalence of Alzheimer's disease, Archer Pharmaceuticals is committed to leveraging existing drugs and developing new, even more effective medications. By addressing this urgent medical need, Archer aims to make a significant impact on the lives of millions affected by Alzheimer's disease worldwide. For more information about Archer Pharmaceuticals and their groundbreaking research, please contact them using the provided details